Cargando…

Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience

Increased amino acid uptake has been demonstrated in intracerebral tumours and head and neck carcinomas of squamous cell origin. We investigated the potential impact of using (18)F-fluoro-ethyl-tyrosine ((18)F-FET)-PET/CT in addition to conventional imaging for gross tumour volume (GTV) delineation...

Descripción completa

Detalles Bibliográficos
Autores principales: Graf, Reinhold, Plotkin, Michail, Nyuyki, Fonyuy, Wust, Peter, Wurm, Reinhard, Budach, Volker, Brenner, Winfried, Fahdt, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502864/
https://www.ncbi.nlm.nih.gov/pubmed/23209892
http://dx.doi.org/10.1155/2012/412585
_version_ 1782250410737664000
author Graf, Reinhold
Plotkin, Michail
Nyuyki, Fonyuy
Wust, Peter
Wurm, Reinhard
Budach, Volker
Brenner, Winfried
Fahdt, Daniel
author_facet Graf, Reinhold
Plotkin, Michail
Nyuyki, Fonyuy
Wust, Peter
Wurm, Reinhard
Budach, Volker
Brenner, Winfried
Fahdt, Daniel
author_sort Graf, Reinhold
collection PubMed
description Increased amino acid uptake has been demonstrated in intracerebral tumours and head and neck carcinomas of squamous cell origin. We investigated the potential impact of using (18)F-fluoro-ethyl-tyrosine ((18)F-FET)-PET/CT in addition to conventional imaging for gross tumour volume (GTV) delineation in stereotactic radiotherapy of skull base tumours. The study population consisted of 14 consecutive patients with cranial base tumours (10 with squamous cell histology, 4 others). All patients underwent a FET-PET/CT examination in addition to contrast-enhanced CT and 11 patients underwent MRI. All tumours and histologic types showed increased FET uptake. The GTV was defined by all voxels showing hyperintensity in MRI or CT (GTV(MRI/CT)) or enhancement in PET (GTV(PET)), forming a GTV(composite) that was used for the initial treatment fields. An additional volume of infiltrative growth outside the GTV(MRI/CT) of about 1.0 ± 2 cm(3) (5% of the conventional volume) was demonstrated by FET-PET only (GTV(PETplus)) with significant enlargement (>10% of GTV(MRI/CT)) in three patients. From existing data, we found correlation between cellular density and the standardized uptake value (SUV) of FET. We were able to substantially reduce the volume of escalated radiation dose (GTV(boost)) by 11 ± 2 cm(3) (24%) of the conventional volume.
format Online
Article
Text
id pubmed-3502864
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35028642012-12-03 Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience Graf, Reinhold Plotkin, Michail Nyuyki, Fonyuy Wust, Peter Wurm, Reinhard Budach, Volker Brenner, Winfried Fahdt, Daniel Int J Mol Imaging Clinical Study Increased amino acid uptake has been demonstrated in intracerebral tumours and head and neck carcinomas of squamous cell origin. We investigated the potential impact of using (18)F-fluoro-ethyl-tyrosine ((18)F-FET)-PET/CT in addition to conventional imaging for gross tumour volume (GTV) delineation in stereotactic radiotherapy of skull base tumours. The study population consisted of 14 consecutive patients with cranial base tumours (10 with squamous cell histology, 4 others). All patients underwent a FET-PET/CT examination in addition to contrast-enhanced CT and 11 patients underwent MRI. All tumours and histologic types showed increased FET uptake. The GTV was defined by all voxels showing hyperintensity in MRI or CT (GTV(MRI/CT)) or enhancement in PET (GTV(PET)), forming a GTV(composite) that was used for the initial treatment fields. An additional volume of infiltrative growth outside the GTV(MRI/CT) of about 1.0 ± 2 cm(3) (5% of the conventional volume) was demonstrated by FET-PET only (GTV(PETplus)) with significant enlargement (>10% of GTV(MRI/CT)) in three patients. From existing data, we found correlation between cellular density and the standardized uptake value (SUV) of FET. We were able to substantially reduce the volume of escalated radiation dose (GTV(boost)) by 11 ± 2 cm(3) (24%) of the conventional volume. Hindawi Publishing Corporation 2012 2012-10-08 /pmc/articles/PMC3502864/ /pubmed/23209892 http://dx.doi.org/10.1155/2012/412585 Text en Copyright © 2012 Reinhold Graf et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Graf, Reinhold
Plotkin, Michail
Nyuyki, Fonyuy
Wust, Peter
Wurm, Reinhard
Budach, Volker
Brenner, Winfried
Fahdt, Daniel
Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience
title Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience
title_full Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience
title_fullStr Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience
title_full_unstemmed Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience
title_short Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience
title_sort contribution of (18)f-fluoro-ethyl-tyrosine positron emission tomography to target volume delineation in stereotactic radiotherapy of malignant cranial base tumours: first clinical experience
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502864/
https://www.ncbi.nlm.nih.gov/pubmed/23209892
http://dx.doi.org/10.1155/2012/412585
work_keys_str_mv AT grafreinhold contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience
AT plotkinmichail contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience
AT nyuykifonyuy contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience
AT wustpeter contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience
AT wurmreinhard contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience
AT budachvolker contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience
AT brennerwinfried contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience
AT fahdtdaniel contributionof18ffluoroethyltyrosinepositronemissiontomographytotargetvolumedelineationinstereotacticradiotherapyofmalignantcranialbasetumoursfirstclinicalexperience